Autonomix Medical, Inc. is a medical device company focused on advancing technologies to develop how diseases involving the nervous system are diagnosed and treated. The Companyâs first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity. It is developing its technology for pancreatic cancer and pancreatitis, conditions that can cause debilitating pain and need an effective solution. Its technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Its development efforts are divided into two parts: diagnostic sensing and therapeutic radiofrequency ablation. The Company is developing Autonomix system, which is primarily catheter-based, meaning that its sensing equipment is delivered to its targeted location via a lumen within the body.
äŒæ¥ã³ãŒãAMIX
äŒç€ŸåAutonomix Medical Inc
äžå Žæ¥Jan 29, 2024
æé«çµå¶è²¬ä»»è
ãCEOãHauser (Bradley)
åŸæ¥å¡æ°8
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jan 29
æ¬ç€Ÿæåšå°21 Waterway Ave, Suite 300
éœåžTHE WOODLANDS
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·77380
é»è©±çªå·18322777816
ãŠã§ããµã€ãhttps://autonomix.com/
äŒæ¥ã³ãŒãAMIX
äžå Žæ¥Jan 29, 2024
æé«çµå¶è²¬ä»»è
ãCEOãHauser (Bradley)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã